NLRP3 and pulmonary arterial hypertension: COVID-19 patients treated with MLT demonstrated satisfactory results in terms of possible preventive measures, a predicted decrease in the intensity of their symptoms, and a possible decrease in immunological diseases.[13] MLT has also been demonstrated to modulate innate and adaptive immune reactions, specifically of the inflammasome NLR family pyrin domain containing 3 (NLRP3); the latter pathway is hyperactivated in COVID-19 patients, contributing to CSS.[13] This inflammasome downregulation reduces pulmonary hypertension (HTN), which occurs at critical stages during SARS-COV-2 infection.